HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development

por Singh, J C, Jhaveri, K, Esteva, F J
Publicado 2014

Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas

por Delpech, Y, Coutant, C, Hsu, L, Barranger, E, Iwamoto, T, Barcenas, C H, Hortobagyi, G N, Rouzier, R, Esteva, F J, Pusztai, L
Publicado 2013

LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer

por Giro-Perafita, A., Luo, L., Khodadadi-Jamayran, A., Thompson, M., Akgol Oksuz, B., Tsirigos, A., Dynlacht, B. D., Sánchez, I., Esteva, F. J.
Publicado 2020

Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

por Esteva, F. J., Baranau, Y. V., Baryash, V., Manikhas, A., Moiseyenko, V., Dzagnidze, G., Zhavrid, E., Boliukh, D., Stroyakovskiy, D., Pikiel, J., Eniu, A. E., Li, R. K., Rusyn, A. V., Tiangco, B., Lee, S. J., Lee, S. Young, Yu, S. Y., Stebbing, J.
Publicado 2019